AbbVie在2025年ASCO会议上展示了针对难治性实体瘤和血液癌症的新数据，突显了其肿瘤学产品组合的广度和深度-动脉网

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

艾伯维等信源发布 2025-05-27 21:06



可切换为仅中文







Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates (ADCs) including telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell lung cancer (NSCLC), ABBV-706 in high-grade neuroendocrine neoplasms (NENs) and pivekimab sunirine (PVEK) in blastic plasmacytoid dendritic cell neoplasm (BPDCN)..

关键的口头报告重点介绍了艾伯维新型研究性抗体药物偶联物（ADC）的新数据，包括telisotuzumab adizutecan（ABBV-400，Temab-A）用于晚期非小细胞肺癌（NSCLC）、ABBV-706用于高级别神经内分泌肿瘤（NEN）以及pivekimab sunirine（PVEK）用于母细胞性浆细胞样树突细胞肿瘤（BPDCN）。

NORTH CHICAGO, Ill.

伊利诺伊州北芝加哥

，

May 27, 2025

2025年5月27日

PRNewswire

美通社

/ -- AbbVie (NYSE: ABBV) today announced that key data from its broad oncology portfolio will be showcased across multiple oral presentations and posters at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (

/ -- 艾伯维（AbbVie，纽约证券交易所代码：ABBV）今天宣布，其广泛的肿瘤学产品组合中的关键数据将在即将召开的美国临床肿瘤学会（ASCO）年会上通过多场口头报告和海报展示呈现。

May 30 - June 3, 2025

2025年5月30日 - 6月3日

). These new data highlight significant progress in AbbVie's robust oncology pipeline, across a range of difficult-to-treat solid tumors and blood cancers.

）。这些新数据突显了艾伯维在多种难治性实体瘤和血液癌症的雄厚肿瘤学管线中取得的重大进展。

'The data we're presenting at this year's ASCO reflect the breadth and depth of our oncology pipeline and our unwavering commitment to research that could transform outcomes for patients facing cancer,' said

“我们在今年的ASCO上展示的数据反映了我们肿瘤学管线的广度和深度，以及我们对可能改变癌症患者预后的研究的坚定承诺，”

Roopal Thakkar

鲁帕尔·塔卡尔

, M.D., executive vice president, research and development and chief scientific officer, AbbVie. 'These presentations underscore our leadership in driving scientific innovation to address some of the most pressing unmet needs in oncology today by leveraging our innovative platforms such as ADCs.'

医学博士，艾伯维执行副总裁，研发和首席科学官。“这些报告强调了我们在推动科学创新方面的领导地位，通过利用我们诸如抗体药物偶联物（ADCs）等创新平台，解决当今肿瘤学领域一些最迫切的未满足需求。”

An oral presentation on investigational telisotuzumab adizutecan (ABBV-400, Temab-A), a next-generation, c-Met directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) payload, will showcase:

一项关于研究性药物telisotuzumab adizutecan（ABBV-400，Temab-A）的口头报告将展示：

Preliminary safety and efficacy results in 41 patients with pre-treated, advanced epidermal growth factor receptor (EGFR)-mutated non-squamous non-small cell lung cancer (NSCLC) from the dose expansion part of a Phase 1 study (

在一项一期研究的剂量扩展部分，41名预先治疗过的晚期表皮生长因子受体（EGFR）突变型非鳞状非小细胞肺癌（NSCLC）患者中获得了初步的安全性和有效性结果。

NCT05029882

）。

Patients received a median of 3 prior lines of therapies and 93% of patients had prior anti-EGFR treatment. The objective response rate (ORR) was 63%.

患者之前接受过的治疗中位数为3种，其中93%的患者曾接受过抗EGFR治疗。客观缓解率（ORR）为63%。

High ORR was observed regardless of c-Met protein expression levels.

无论c-Met蛋白表达水平如何，都观察到了较高的ORR。

At the time of data cut-off, 54% of responders experienced a ≥6 months duration of response (DoR).

截至数据截止时，54%的应答者经历了至少6个月的反应持续时间（DoR）。

The most common any-grade TEAEs in ≥30% of patients were anemia (63%), nausea (61%), vomiting (37%), decreased appetite (34%), and neutropenia (34%).

在≥30%的患者中，最常见的任何等级的治疗期间出现的不良事件（TEAE）为贫血（63%）、恶心（61%）、呕吐（37%）、食欲减退（34%）和中性粒细胞减少（34%）。

Additional data with 4 months follow-up will be presented at ASCO.

额外的随访4个月的数据将在ASCO会议上展示。

Temab-A is also being evaluated in multiple ongoing

Temab-A 也在多个正在进行的评估中。

clinical trials

临床试验

including a Phase 1/2 Study (

包括 1/2 期研究 (

NCT06772623

) in first-line NSCLC without actionable genomic alterations in combination with budigalimab (AbbVie's investigational programmed cell death 1 inhibitor), a Phase 2 study (

）在无可行基因组改变的一线非小细胞肺癌中与 budigalimab（AbbVie 的研究性程序性细胞死亡 1 抑制剂）联合使用，一项 2 期研究（

NCT06107413

) in second-line metastatic colorectal cancer (CRC) in combination with fluorouracil, folinic acid and bevacizumab, and a Phase 3 study (

）用于二线转移性结直肠癌（CRC），与氟尿嘧啶、亚叶酸钙和贝伐单抗联合使用，并进行了3期研究（

NCT06614192

) as monotherapy in patients with c-Met overexpressing refractory metastatic CRC.

) 作为单一疗法用于c-Met过表达的难治性转移性结直肠癌患者。

'The anti-tumor activity of Temab-A in patients with pre-treated, advanced EGFR-mutated non-squamous NSCLC is encouraging and supports further exploration of this novel ADC in this setting,' said

“Temab-A在先前接受过治疗的晚期EGFR突变非鳞状非小细胞肺癌患者中展现出令人鼓舞的抗肿瘤活性，这支持了在此背景下对这种新型ADC的进一步探索，”表示

Ross Camidge

罗斯·卡米奇

, M.D., Ph.D,

，医学博士，哲学博士，

University of Colorado

科罗拉多大学

Cancer Center,

癌症中心，

United States

美国

and principal investigator of the trial. 'Temab-A appears to have a manageable safety profile and continues to show promising clinical activity in advanced NSCLC, which is associated with poor prognosis.'

并且是试验的首席研究员。‘Temab-A似乎具有可管理的安全性，并且在与预后不良相关的晚期非小细胞肺癌中继续显示出有希望的临床活性。’

Additional oral presentations will highlight new safety and efficacy data for ABBV-706, a SEZ6-directed ADC with a Top1i payload, and pivekimab sunirine (PVEK), a novel ADC designed to target CD123:

其他口头报告将重点介绍ABBV-706（一种以SEZ6为靶点、携带Top1i有效载荷的抗体药物偶联物）和Pivekimab Sunirine（PVEK）（一种旨在靶向CD123的新型抗体药物偶联物）的新安全性和有效性数据。

In a Phase 1 open-label study of ABBV-706 monotherapy, 64 patients with high-grade neuroendocrine neoplasms (NENs), a diverse group of rare and aggressive solid tumors, received ABBV-706 monotherapy IV at 1.3–3.5 mg/kg once every 3 weeks.

在ABBV-706单药治疗的1期开放标签研究中，64名高级别神经内分泌肿瘤（NENs）患者接受了ABBV-706单药治疗，这些患者患有一组多样化的罕见且侵袭性的实体瘤，治疗剂量为1.3–3.5 mg/kg，每3周一次静脉注射。

2,3

The entire cohort had an ORR of 31.3%, and a median DoR of 5.6 months.

整个队列的ORR为31.3%，中位DoR为5.6个月。

The most common grade ≥3 TEAEs (cumulative across all dose levels), were anemia (45%), neutropenia (33%), and thrombocytopenia (21%).

最常见的3级或以上TEAE（所有剂量水平的累积）为贫血（45%）、中性粒细胞减少（33%）和血小板减少（21%）。

Additional data will be presented at ASCO.

更多数据将在ASCO上公布。

This ongoing study (

这项正在进行的研究 (

NCT05599984

) is evaluating ABBV-706 as monotherapy, or in combination with budigalimab, carboplatin, or cisplatin, in patients with advanced solid tumors expressing SEZ6, including small-cell lung cancer, NENs and high-grade Central Nervous System tumors.

）正在评估ABBV-706作为单药疗法，或与budigalimab、卡铂或顺铂联合使用，用于治疗表达SEZ6的晚期实体瘤患者，包括小细胞肺癌、神经内分泌肿瘤（NEN）和高级别中枢神经系统肿瘤。

Results from the open-label, multicenter Phase

开放标签、多中心阶段的结果

/2 CADENZA trial (

/2 CADENZA 试验 (

NCT03386513

) of PVEK monotherapy in patients with previously untreated or relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN), a highly aggressive and rare type of blood cancer, demonstrated clinical benefit.

）PVEK单药治疗既往未治疗或复发/难治性（R/R）母细胞性浆细胞样树突状细胞肿瘤（BPDCN，一种高度侵袭性和罕见的血液癌症）患者，显示出临床益处。

4,5

4，5

The results show that among 33 untreated patients, the primary endpoint of composite complete response (CCR) rate, defined as CR + clinical CR (CR with minimal skin abnormality), was 70% (95% CI, 51.3-84.4) with a median duration of CCR of 9.8 months. ORR was 85%.

结果显示，在33名未接受治疗的患者中，主要终点综合完全缓解（CCR）率为70%（95%置信区间，51.3-84.4），其中CCR定义为完全缓解（CR）+临床完全缓解（伴有轻微皮肤异常的CR），CCR的中位持续时间为9.8个月。总缓解率（ORR）为85%。

In the 51 patients with R/R BPDCN, the CCR rate was 14% with a median duration of CCR of 9.2 months. ORR was 35%.

在51名R/R BPDCN患者中，CCR率为14%，CCR的中位持续时间为9.2个月。ORR为35%。

Among all the 84 patients enrolled, the most common grade ≥3 TEAEs were peripheral edema (12%).

在所有入组的84名患者中，最常见的3级或以上TEAE是外周水肿（12%）。

TEAEs led to discontinuation in 9% and 7% of patients with first-line and R/R BPDCN, respectively.

TEAEs导致一线和R/R BPDCN患者中分别有9%和7%的患者停止治疗。

Additional data will be presented at ASCO.

更多信息将在ASCO上公布。

PVEK is also being evaluated in a Phase 1/2 study (

PVEK也正在一项1/2期研究中进行评估 (

NCT04086264

) in R/R and newly diagnosed acute myeloid leukemia.

在R/R和新诊断的急性髓系白血病中。

'Over the past few years, we've significantly expanded our ADC portfolio to investigate a broad range of solid tumors and blood cancers, reflecting our deep commitment to transforming cancer care through targeted therapies and biomarker driven approaches,' said Daejin Abidoye, M.D., vice president, therapeutic area head of solid tumors, AbbVie.

“过去几年，我们大幅扩展了ADC产品组合，以研究多种实体瘤和血液癌症，这反映了我们通过靶向治疗和生物标志物驱动方法来变革癌症治疗的深厚承诺，”艾伯维公司实体瘤治疗领域负责人、副总裁Daejin Abidoye博士表示。

'These results highlight the potential of our investigational medicines to offer a meaningful clinical benefit in multiple difficult-to-treat cancers, where current treatment options are limited.'.

“这些结果突显了我们的研究性药物在多种难以治疗的癌症中提供有意义的临床益处的潜力，而目前的治疗选择有限。”

Further information on AbbVie clinical trials is available at

有关艾伯维临床试验的更多信息，请访问

https://www.clinicaltrials.gov/

。

Additional details on key presentations at ASCO are available below and the full ASCO Annual Meeting 2025 abstracts are available

以下是ASCO重点报告的更多详细信息，完整的ASCO 2025年度会议摘要可供查阅。

here

这里

。

Title

标题

Date/Time

日期/时间

Session

会话

Abstract

摘要

Number

数字

Telisotuzumab adizutecan (ABBV-400; Temab-A)

特利索珠单抗阿迪祖替康 (ABBV-400; Temab-A)

monotherapy vs trifluridine/tipiracil plus bevacizumab in

单药治疗与曲氟尿苷/替吡嘧啶联合贝伐珠单抗在

patients with refractory metastatic colorectal cancer with

难治性转移性结直肠癌患者

increased c-Met protein expression: An open-label,

增加c-Met蛋白表达：一项开放标签，

randomized, phase 3 trial.

随机、三期试验。

Saturday, May 31,

星期六，五月三十一日，

9:00 AM – 12:00

上午9:00 – 中午12:00

PM CDT

下午中部夏令时间

Poster Board: 303a

海报板：303a

TPS3635

Telisotuzumab adizutecan (ABBV-400; Temab-A) in

特利索珠单抗阿迪祖替康 (ABBV-400; Temab-A) 在

combination with fluorouracil, leucovorin, and budigalimab

氟尿嘧啶、亚叶酸和布地加利单抗联合用药

in locally advanced/metastatic gastric, gastroesophageal

局部晚期/转移性胃癌、胃食管结合部癌

junction, or esophageal adenocarcinoma (a/m GEA).

交界处或食管腺癌（a/m GEA）。

Saturday, May 31,

星期六，五月三十一日，

9:00 AM – 12:00

上午9:00 - 12:00

PM CDT

下午中部夏令时间

Poster Board: 491b

海报板：491b

TPS4202

Efficacy and safety of first-line ibrutinib plus venetoclax in

一线伊布替尼联合维奈托克的疗效和安全性

patients with mantle cell lymphoma (MCL) who were older

患有套细胞淋巴瘤（MCL）且年龄较大的患者

or had TP53 mutations in the SYMPATICO study.

或在SYMPATICO研究中存在TP53突变。

Saturday, May 31,

星期六，五月三十一日，

9:12 – 9:18 AM

上午9:12 - 9:18

CDT

中国标准时间

Rapid Oral Abstract

快速口头摘要

Session

会话

Hematologic Malignancies—

血液系统恶性肿瘤—

Lymphoma and

淋巴瘤和

Chronic

慢性

Lymphocytic

淋巴细胞的

Leukemia

白血病

7017

LUMINOSITY, a phase 2 study of telisotuzumab vedotin in

LUMINOSITY，telisotuzumab vedotin 的二期研究

patients with c-Met protein–overexpressing non-

c-Met蛋白过表达的非患者

squamous EGFR-wildtype advanced NSCLC: Efficacy

鳞状EGFR野生型晚期NSCLC：疗效

outcomes by prior therapy.

既往治疗的结果。

Saturday,

星期六，

May 31,

5月31日，

1:30 – 4:30 PM CDT

下午1:30 – 下午4:30 中央夏令时间

Poster Board: 98

海报板：98

8618

Long-term efficacy and safety of etentamig, a B-cell

长期疗效和安全性评估：Etentamig，一种B细胞

maturation antigen (BCMA) bispecific antibody in patients

患者中的成熟抗原（BCMA）双特异性抗体

with relapsed/refractory multiple myeloma (RRMM).

复发/难治性多发性骨髓瘤（RRMM）。

Sunday,

星期日，

June 1,

6月1日，

9:00 AM – 12:00

上午9:00 – 12:00

PM CDT

下午中部夏令时间

Poster Board: 95

海报板：95

7527

Novel analysis of 3-y results from the pivotal EPCORE

对关键的EPCORE三年结果的新颖分析

NHL-1 study: Outcomes in patients (pts) with

NHL-1研究：患者（pts）的结果

relapsed/refractory large B-cell lymphoma (R/R LBCL)

复发/难治性大B细胞淋巴瘤 (R/R LBCL)

and complete response (CR) at 2 y with epcoritamab

并在 2 年时使用 epcoritamab 达到完全缓解 (CR)

(epcor) monotherapy.

（epcor）单药治疗。

Sunday,

星期日，

June 1,

6月1日，

9:00 AM – 12:00

上午9:00 – 中午12:00

PM CDT

下午中央夏令时间

Poster Board: 226

海报板：226

7043

Folate receptor alpha (FRα; FOLR1) expression and

叶酸受体α（FRα；FOLR1）表达和

persistence in ovarian cancer in clinical trial samples and

在卵巢癌的临床试验样本中持续存在并且

real-world patient cohort.

真实世界患者队列。

Sunday,

星期日，

June 1,

6月1日，

9:00 AM – 12:00

上午9:00 – 12:00

PM CDT

下午中部夏令时间

Poster Board: 489

海报板：489

5591

Efficacy of third-line and later (3L+) therapies post poly

聚类后三线及以后 (3L+) 疗法的疗效

(ADP-ribose) polymerase inhibitor (PARPi) exposure in

(ADP-核糖)聚合酶抑制剂（PARPi）暴露于

recurrent platinum-sensitive ovarian cancer (PSOC): A

复发性铂敏感卵巢癌 (PSOC)：A

pooled clinical trial database analysis.

汇总的临床试验数据库分析。

Sunday,

星期日，

June 1,

6月1日，

9:00 AM – 12:00

上午9:00 – 12:00

PM CDT

下午 CDT

Poster Board: 477

海报板：477

5579

A phase 1 first-in-human study evaluating safety,

评估安全性的第一阶段首次人体研究，

pharmacokinetics, and efficacy of ABBV-291, a CD79b-

药代动力学和ABBV-291（一种CD79b-）的功效

targeting antibody-drug conjugate, in patients with

靶向抗体药物偶联物，在患者中

relapsed/refractory B-cell non-Hodgkin lymphoma.

复发/难治性B细胞非霍奇金淋巴瘤。

Sunday,

星期日，

June 1,

6月1日，

9:00 AM – 12:00

上午9:00 – 12:00

PM CDT

中央夏令时下午

Poster Board: 271a

海报板：271a

TPS7093

Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met

Telisotuzumab adizutecan (ABBV-400; Temab-A)，一种c-Met

protein–targeting antibody-drug conjugate (ADC), in

蛋白质靶向抗体药物偶联物 (ADC)，在

patients (pts) with advanced EGFR-mutated (MT) non-

患有晚期EGFR突变（MT）的非小细胞肺癌患者（pts）

squamous (NSQ) non-small cell lung cancer (NSCLC):

鳞状（NSQ）非小细胞肺癌（NSCLC）：

Results from a phase 1 study.

1期研究的结果。

Monday,

星期一，

June 2,

6月2日，

8:00 – 8:06 AM

早上8:00 – 8:06

CDT

中国标准时间

Rapid Oral Abstract

快速口头摘要

Session

会话

Lung Cancer—

肺癌——

Non-Small Cell

非小细胞

Metastatic

转移性

8512

Phase 1, open-label, first-in-human study of ABBV-969, a

第一阶段，开放标签，ABBV-969的首次人体研究，

dual variable antibody-drug conjugate, in

双变量抗体药物偶联物，在

patients with metastatic castration-resistant prostate

转移性去势抵抗性前列腺癌患者

cancer.

癌症。

Monday,

星期一，

June 2,

6月2日，

9:00 AM – 12:00

上午9:00 - 中午12:00

PM CDT

中央夏令时下午

Poster Board: 309b

海报板：309b

TPS5111

A phase 2, open-label, randomized study of livmoniplimab

一项二期、开放标签、随机研究的利夫莫尼普利单抗

in combination with budigalimab versus chemotherapy in

与化疗相比，与布地单抗联合使用

patients with metastatic urothelial carcinoma.

转移性尿路上皮癌患者。

Monday,

星期一，

June 2,

6月2日，

9:00 AM – 12:00

上午9:00 – 中午12:00

PM CDT

下午中部夏令时间

Poster Board: 414b

海报板：414b

TPS4618

Safety and efficacy of ABBV-706, a seizure-related

ABBV-706 的安全性和有效性，一种与癫痫发作相关的

homolog protein (SEZ6)- targeting antibody-drug

同源蛋白（SEZ6）靶向抗体药物

conjugate, in high-grade neuroendocrine neoplasms.

在高级别神经内分泌肿瘤中结合使用。

Monday,

星期一，

June 2,

6月2日，

10:09 – 10:21 AM

上午10:09 – 10:21

CDT

中国标准时间

Oral Presentation

口头报告

Clinical Science

临床科学

Symposium – ADC

研讨会 – ADC

2.0: Discovering

发现

the Targets That

目标

Will Change the

将会改变

Game

游戏

105

Efficacy and safety of pivekimab sunirine (PVEK) in

Pivekimab sunirine（PVEK）的有效性和安全性在

patients (pts) with blastic plasmacytoid dendritic cell

浆细胞样树突细胞原生性患者

neoplasm (BPDCN) in the CADENZA study.

CADENZA 研究中的肿瘤（BPDCN）。

Monday,

星期一，

June 2,

6月2日，

3:24 – 3:36 PM

下午3点24分至3点36分

CDT

中国时间 (China Time)

Oral Presentation

口头报告

Oral Abstract

口头摘要

Session –

会话 –

Hematologic

血液学的

Malignancies—

恶性肿瘤——

Leukemia,

白血病，

Myelodysplastic

骨髓增生异常

Syndromes, and

综合征，以及

Allotransplant

同种异体移植

6502

Telisotuzumab adizutecan, ABBV-706, pivekimab sunirine, etentamig, livmoniplimab, budigalimab, ABBV-291 and ABBV-969 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies..

Telisotuzumab adizutecan、ABBV-706、pivekimab sunirine、etentamig、livmoniplimab、budigalimab、ABBV-291 和 ABBV-969 是研究性药物，尚未获得全球任何卫生部门的批准。这些研究性药物的安全性和有效性正在作为持续临床研究的一部分进行评估。

Venetoclax, ibrutinib, epcoritamab, telisotuzumab vedotin are approved medicines being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses.

维奈托克、伊布替尼、埃波利单抗和替利珠单抗维多汀是已获批药物，正在研究其额外用途。这些未获批的额外用途尚未确立安全性和有效性。

EPKINLY

艾培昔单抗

/TEPKINLY

(epcoritamab) is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.

（epcoritamab）由Genmab和AbbVie共同开发，作为双方肿瘤学合作的一部分。两家公司在美国和日本共同承担商业责任，而AbbVie负责进一步的全球商业化。

VENCLEXTA

维奈托克

/VENCLYXTO

(venetoclax) is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

(venetoclax)由AbbVie和罗氏开发。在美国，它由AbbVie和罗氏集团成员Genentech共同商业化，在美国以外则由AbbVie负责。

IMBRUVICA

伊布替尼

(ibrutinib) is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc.

(伊布替尼)由AbbVie旗下的Pharmacyclics LLC和Janssen Biotech, Inc.共同开发和商业化。

U.S. Prescribing Information for AbbVie Medicines

美国AbbVie药品处方信息

Please see full

请查看完整内容

Prescribing Information

处方信息

for EMRELIS

适用于 EMRELIS

™

(telisotuzumab vedotin-tllv)

(特利索图珠单抗维多汀-tllv)

Please see full

请查看完整内容

Prescribing Information

处方信息

for EPKINLY

适用于EPKINLY

(epcoritamab-bysp)

（依帕塔单抗-bysp）

Please see full

请查看完整内容

Prescribing Information

处方信息

for IMBRUVICA

适用于IMBRUVICA

(ibrutinib)

(依鲁替尼)

Please see full

请看完整内容

Prescribing Information

处方信息

for VENCLEXTA

适用于VENCLEXTA

(venetoclax tablets)

（维奈托克片）

About AbbVie

关于艾伯维

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio.

艾伯维的使命是发现并提供创新药物和解决方案，以解决当今严重的健康问题，并应对未来的医疗挑战。我们力求在包括免疫学、肿瘤学、神经科学和眼科在内的几个关键治疗领域对人们的生活产生显著影响，并且我们在艾尔建美学产品组合中的产品和服务也致力于此。

For more information about AbbVie, please visit us at .

欲了解有关艾伯维的更多信息，请访问我们的网站。

www.abbvie.com

. Follow @abbvie on

关注 @abbvie

LinkedIn,

LinkedIn，

Facebook

，

Instagram

图享

，

X (formerly Twitter)

X（前身为 Twitter）

and

和

YouTube.

YouTube。

About AbbVie in Oncology

关于艾伯维在肿瘤学领域

AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination.

艾伯维致力于提升护理标准，并为全球患有难治癌症的患者带来变革性的疗法。我们正在推进一系列癌症类型的调查性疗法的动态管线，涵盖血液癌和实体瘤。我们专注于创造靶向药物，这些药物要么阻碍癌细胞的复制，要么助力其清除。

We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines..

我们通过各种有针对性的治疗方式和生物干预措施来实现这一目标，包括小分子治疗药物、抗体药物偶联物 (ADC)、基于免疫肿瘤学的治疗药物、多特异性抗体以及新型 CAR-T 平台。我们敬业且经验丰富的团队与创新合作伙伴携手，加速潜在突破性药物的交付。

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines.

如今，我们庞大的肿瘤学产品组合包括已获批和正在研究的针对多种血液癌症和实体肿瘤的治疗方法。我们正在针对一些全球最普遍和最具衰弱性的癌症进行多项临床试验，评估超过35种研究性药物。在努力对人们的生活产生显著影响的同时，我们致力于探索解决方案，帮助患者获得我们的抗癌药物。

For more information, please visit .

如需更多信息，请访问。

http://www.abbvie.com/oncology

。

Forward-Looking Statements

前瞻性声明

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements.

本新闻稿中的某些陈述，或可能被视为《1995年私人证券诉讼改革法案》意义上的前瞻性陈述。 “相信”、“预期”、“预见”、“预计”等词语及类似表达和未来或条件动词的使用，通常用于识别前瞻性陈述。

AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations.

AbbVie提醒，这些前瞻性陈述受到可能导致实际结果与前瞻性陈述中明示或暗示的结果存在重大差异的风险和不确定性的影响。这些风险和不确定性包括但不限于知识产权方面的挑战、来自其他产品的竞争、研发过程中固有的困难、不利的诉讼或政府行为、适用于我们行业的法律法规的变化、全球宏观经济因素的影响（如经济衰退或不确定性）、国际冲突、贸易争端和关税，以及与全球业务运营相关的其他不确定性和风险。

Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, 'Risk Factors,' of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information.

有关可能影响艾伯维运营的经济、竞争、政府、技术及其他因素的更多信息，请参阅艾伯维2024年Form 10-K年度报告的第1A项“风险因素”，该报告已提交给美国证券交易委员会，并通过其Form 10-Q季度报告以及随后向美国证券交易委员会提交的更新、补充或取代该信息的其他文件进行了更新。

AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. .

AbbVie 不承担任何义务，并明确拒绝因后续事件或发展而公开发布对前瞻性陈述的任何修订，除非法律要求。

References:

参考文献：

Camidge R, Raimbourg J, Lee Y-G, et al. Telisotuzumab Adizutecan (ABBV-400; Temab-A), a c-Met Protein-Targeting Antibody-Drug Conjugate, in Patients With Advanced EGFR Mutated Non-Squamous NSCLC: Results From a Phase 1 Study. Abstract 8512 presented at the American Society of Clinical Oncology Annual Meeting, 2025.

坎布里奇 R、雷姆堡 J、李英杰等。Telisotuzumab Adizutecan（ABBV-400；Temab-A），一种靶向c-Met蛋白的抗体药物偶联物，用于治疗晚期EGFR突变非鳞状非小细胞肺癌患者：一项1期研究结果。摘要8512，在2025年美国临床肿瘤学会年会上发表。

。

Chicago, Illinois

伊利诺伊州芝加哥市

。

Cooper A, Chandana S, Furqan M, et al. Safety and efficacy of ABBV-706, a seizure-related homolog protein (SEZ6)- targeting antibody-drug conjugate, in high-grade neuroendocrine neoplasms. Abstract 105 presented at the American Society of Clinical Oncology Annual Meeting, 2025.

库珀 A、钱达纳 S、弗尔干 M 等。ABBV-706（一种针对癫痫相关同源蛋白（SEZ6）的抗体药物偶联物）在高级别神经内分泌肿瘤中的安全性和有效性。摘要 105，发表于2025年美国临床肿瘤学会年会。

Chicago, Illinois

伊利诺伊州芝加哥市

。

Sultana Q, Kar J, Verma A, et al. A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management. J Clin Med. 2023

Sultana Q, Kar J, Verma A, 等。神经内分泌肿瘤的综合综述：表现、病理生理学与治疗。《临床医学杂志》。2023年。

Aug 5

8月5日

;12(15):5138. doi: 10.3390/jcm12155138.

Pemmaraju N, Marconi G, Montesinos P, et al. Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study. Abstract 6502 presented at the American Society of Clinical Oncology Annual Meeting, 2025.

Pemmaraju N, Marconi G, Montesinos P, 等。Pivekimab sunirine (PVEK) 在伴有母细胞样浆细胞样树突细胞肿瘤（BPDCN）患者中的疗效与安全性：CADENZA 研究。摘要 6502，发表于2025年美国临床肿瘤学会年会。

Chicago, Illinois

伊利诺伊州芝加哥市

。

Cazzato G, Capuzzolo M, Bellitti E, et al. Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview. Hematol Rep 2023;15(4):696-706 doi: 10.3390/hematolrep15040070.

Cazzato G, Capuzzolo M, Bellitti E, 等。母细胞样浆细胞样树突细胞肿瘤 (BPDCN)：临床特征与组织病理学及治疗概述。《血液学报告》2023;15(4):696-706 doi: 10.3390/hematolrep15040070。

Contacts:

联系人：

Media:

媒体：

Investors:

投资者：

Sourojit (Jit) Bhowmick, Ph.D.

苏罗吉特（Jit）·鲍米克，博士

Liz Shea

莉兹·谢亚

jit.bhowmick@abbvie.com